Table 1. Detailed patient characteristics and treatment outcomes.

Patient	Age	ECOG PS & Comorbidity	Number of previous lines of platinum for recurrent disease	Response to last line platinum (Imaging and/or CA125)	Number of olaparib cycles & best response (Imaging and/or CA125)	Grade 3-4 toxicities	Grade 1-2 toxicities	Reason for discontinuation	Dose level
1	67	1—none	6	PR	0—permanent discontinuation due to allergic reaction	none	Gr. 2 urticaria due allergic reaction	Toxicity	0
2	68	1—Asthma, atrial fibrillation, short bowel-syndrome	1	PR	2—PD	none	none	Progressive disease	0
3	85	0—asthma, arthrosis, dyspepsia	1	PR	2—SD	Gr. 3 nausea	Gr. 2 fatigue, gr. 2 depression	Toxicity	−2
4	65	1—none	1	PR	3—SD	Gr. 3 anemia	Gr. 2 nausea, gr. 2 dizziness	Toxicity	−1
5	77	0—Atrial fibrillation, dyslipidemia, angina pectoris, arthrosis	1	PR	3—SD	Gr. 3 infection	Gr. 2 fatigue, gr. 1 anemia	Toxicity	0
6	79	1—surgery and adjuvant chemotherapy for colorectal cancer (2013), deep venous thrombosis and lung embolism	1	PR	3—SD	Gr. 3 fatigue	Gr. 2 nausea, gr. 2 diarrhea, gr.2 weight loss, gr. 2 anemia	Toxicity	−2
7	66	1—Asthma	1	PR	4—PD	none	Gr. 2 nausea, gr. 1 fatigue, gr. 1 neutropenia	Progressive disease	−2
8	75	1—none	2	PR	4—PD	none	Gr. 1 fatigue	Progressive disease	0
9	77	1—none	1	PR	4—PD	Gr. 3 febrile neutropenia	none	Progressive disease	−1
10	66	2—heart failure, hypothyreosis	1	PR	6—SD	none	Gr. nausea, gr. 1 fatigue	Progressive disease	−2
11	72	2—Chronic obstructive pulmonary disease, osteoporosis, sarcopenia, hypertension, depression, early breast cancer—received adj. chemotherapy, radiotherapy, aromatase inhibitor and trastuzumab (2016).	1	PR	7—SD	none	Gr. 2 nausea, gr. 1 fatigue	Progressive disease	−2
12	70	0—none	1	PR	8—SD	none	Gr. 1 fatigue, gr. 1 myalgia, gr. 1 abdominal pain	Progressive disease	0
13	73	0—dyslipidemia, osteoporosis	2	PR	9—SD	none	Gr. 1 fatigue, gr. 1 nausea, gr. 1 neutropenia	Ongoing	−1
14	71	0—osteoporosis, transient ischemic attack, lung embolism	4	PR	9—SD	none	Gr. 1 headache, gr. 1 fatigue, gr. 1 dyspnea gr. 1 blurred vision	Ongoing	0
15	67	1—breast cancer (2000)	1	PR	12—SD	none	Gr. 1 abdominal pain, gr. 1 nausea, gr.1 fatigue	Ongoing	0
16	77	1—hypertension	2	CR	14—SD	none	Gr. 1 anemia, gr. 1 fatigue, gr. 1 nausea	Ongoing	−2
17	78	1—pulmonary embolism, lung cancer (St.I) accidental fund—removed by surgery	2	CR	15—SD	none	Gr. 2 nausea, gr. 2 fatigue, gr. 1 elevated se- creatinine	Ongoing	−2
18	74	0—hypertension	1	CR	19—SD	Gr. 3 anemia	Gr. 1 nausea	Ongoing	−2
19	80	1—early breast cancer (1991)	1	CR	29—SD	none	Gr. 1 fatigue, gr. 1 diarrhea, gr. 1 nausea, gr. 1 dizziness, gr. 1 alopecia, gr. 2 neutropenia	Progressive disease	−2
20	77	1—hypertension, early breast cancer (2006)	1	CR	31—SD	none	Gr. 2 nausea, gr. 2 fatigue, gr. 1 elevated se- creatinine	Ongoing	−2